Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGN NASDAQ:CODX NASDAQ:FEMY NASDAQ:LFWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$0.37-6.1%$0.42$0.27▼$3.23$5.69M1.5742,541 shs39,935 shsCODXCo-Diagnostics$5.63-2.3%$2.83$1.26▼$46.50$21.23M2.7417.04 million shs660,497 shsFEMYFemasys$0.31-14.2%$0.40$0.29▼$1.11$21.57M-2.232.08 million shs2.58 million shsLFWDLifeward$7.01-2.2%$6.93$4.14▼$15.00$20.18M0.3611,901 shs10,555 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-1.25%-2.49%-1.30%-34.83%-82.05%CODXCo-Diagnostics+11.41%-48.53%+262.26%+172.99%-33.49%FEMYFemasys-2.96%-5.90%-10.59%-32.60%-55.35%LFWDLifeward-1.51%-9.70%+2.43%+19.30%-51.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$0.37-6.1%$0.42$0.27▼$3.23$5.69M1.5742,541 shs39,935 shsCODXCo-Diagnostics$5.63-2.3%$2.83$1.26▼$46.50$21.23M2.7417.04 million shs660,497 shsFEMYFemasys$0.31-14.2%$0.40$0.29▼$1.11$21.57M-2.232.08 million shs2.58 million shsLFWDLifeward$7.01-2.2%$6.93$4.14▼$15.00$20.18M0.3611,901 shs10,555 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-1.25%-2.49%-1.30%-34.83%-82.05%CODXCo-Diagnostics+11.41%-48.53%+262.26%+172.99%-33.49%FEMYFemasys-2.96%-5.90%-10.59%-32.60%-55.35%LFWDLifeward-1.51%-9.70%+2.43%+19.30%-51.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 2.00Hold$11.502,999.73% UpsideCODXCo-Diagnostics 2.00Hold$67.501,098.93% UpsideFEMYFemasys 2.50Moderate Buy$5.331,640.64% UpsideLFWDLifeward 1.67Reduce$10.0043.06% UpsideCurrent Analyst Ratings BreakdownLatest CLGN, CODX, FEMY, and LFWD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026LFWDLifeward Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/26/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026CLGNCollPlant Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026LFWDLifeward Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CLGNCollPlant Biotechnologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/19/2026LFWDLifeward HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$389K13.75N/AN/A$0.48 per share0.77CODXCo-Diagnostics$718.17K28.89N/AN/A$9.14 per share0.62FEMYFemasys$2.29M8.08N/AN/A$0.10 per share3.06LFWDLifeward$20.92M0.94N/AN/A$5.52 per share1.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$11.49M-$1.45N/AN/AN/A-683.68%-218.81%-139.28%8/20/2026 (Estimated)CODXCo-Diagnostics-$46.90M-$15.77N/AN/AN/A-6,760.63%-164.92%-141.15%8/14/2026 (Estimated)FEMYFemasys-$18.63M-$0.27N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)LFWDLifeward-$19.91M-$19.66N/AN/AN/A-123.66%-243.14%-97.39%8/13/2026 (Estimated)Latest CLGN, CODX, FEMY, and LFWD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2026Q1 2026CLGNCollPlant Biotechnologies-$0.2374-$0.23+$0.0074-$0.23$0.46 million$0.07 million5/15/2026Q1 2026LFWDLifeward-$1.18-$6.70-$5.52-$6.70$5.78 million$3.92 million5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 million5/8/2026Q1 2026FEMYFemasys-$0.0667$0.0049+$0.0716N/A$0.77 million$0.42 million3/31/2026Q4 2025CODXCo-Diagnostics-$3.90-$16.65-$12.75-$16.65$0.13 million$0.26 million3/31/2026Q4 2025FEMYFemasys-$0.0833-$0.01+$0.0733-$0.01$1.06 million$0.81 million3/19/2026Q4 2025LFWDLifeward-$0.07-$3.60-$3.53-$3.60$7.87 million$5.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/ALFWDLifewardN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A2.272.31CODXCo-DiagnosticsN/A2.282.09FEMYFemasys0.533.911.98LFWDLifeward1.162.401.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%CODXCo-Diagnostics14.99%FEMYFemasys65.27%LFWDLifeward26.76%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%CODXCo-Diagnostics5.40%FEMYFemasys7.55%LFWDLifeward1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7014.42 million13.03 millionOptionableCODXCo-Diagnostics1003.69 million3.49 millionOptionableFEMYFemasys3060.39 million55.83 millionNot OptionableLFWDLifeward602.81 million2.77 millionOptionableCLGN, CODX, FEMY, and LFWD HeadlinesRecent News About These CompaniesLifeward (LFWD) Q4 2025 Earnings TranscriptMay 22, 2026 | fool.comLifeward Ltd.: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed PlatformMay 19, 2026 | finanznachrichten.deLifeward Names Keith D. Rose as Chief Medical OfficerMay 19, 2026 | tipranks.comLifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed PlatformMay 19, 2026 | globenewswire.comLifeward: Q1 Earnings SnapshotMay 17, 2026 | khou.comKLifeward expects 2026 revenue similar to 2025 following Oratech acquisition and $10M convertible note financingMay 17, 2026 | seekingalpha.comLifeward (LFWD) Q1 2026 Earnings TranscriptMay 17, 2026 | finance.yahoo.comHow The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation AssumptionsMay 17, 2026 | finance.yahoo.comLifeward Ltd. (NASDAQ:LFWD) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comLifeward Earnings Call Balances Growth With DisruptionsMay 15, 2026 | tipranks.comLifeward (LFWD) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2026 | zacks.comLifeward Delays Quarterly Report Amid Deal AccountingMay 15, 2026 | tipranks.comLifeward Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comLifeward Q1 earnings previewMay 14, 2026 | msn.comLifeward to Report First Quarter 2026 Financial Results on May 15, 2026May 11, 2026 | globenewswire.comLifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered ExoskeletonMay 4, 2026 | globenewswire.comLifeward Ltd.April 7, 2026 | edition.cnn.comOramed Completes Oratech Sale and Strategic Lifeward FinancingMarch 31, 2026 | tipranks.comLifeward (LFWD) price target increased by 344.44% to 20.40March 27, 2026 | msn.comLifeward Successfully Closes on Strategic Partnership with OramedMarch 25, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Before the Moon Base Gets Built, These 4 Companies WinBy Thomas Hughes | May 11, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026CLGN, CODX, FEMY, and LFWD Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$0.37 -0.02 (-6.05%) Closing price 04:00 PM EasternExtended Trading$0.37 -0.01 (-1.35%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Co-Diagnostics NASDAQ:CODX$5.63 -0.13 (-2.26%) Closing price 04:00 PM EasternExtended Trading$5.75 +0.12 (+2.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Femasys NASDAQ:FEMY$0.31 -0.05 (-14.22%) Closing price 04:00 PM EasternExtended Trading$0.30 -0.01 (-3.07%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Lifeward NASDAQ:LFWD$7.01 -0.16 (-2.23%) Closing price 03:58 PM EasternExtended Trading$7.20 +0.19 (+2.64%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
